LLY vs NVO: How Eli Lilly and Novo Nordisk Compare (2026)
Short answer
LLY (Eli Lilly) and NVO (Novo Nordisk) are often compared because they share investment themes, but they are different businesses. Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Neither is universally better: pick by which thesis you are expressing and what you already own. This is descriptive, not a recommendation.
What does Eli Lilly (LLY) do?
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
LLY vs NVO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Eli Lilly is best understood through its own drivers, and Novo Nordisk through its. The useful comparison is which set of drivers and risks you want exposure to.
- LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
LLY or NVO: which should you pick?
The bottom line: LLY vs NVO
LLY and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and NVO exposure against your real portfolio. It is not an investment adviser.
Build a basket around LLY with Walnut
Use Eli Lilly as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between LLY and NVO?
+
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is LLY or NVO the better stock?
+
Walnut is informational, not investment advice. Neither is universally better; LLY and NVO suit different views and risk levels. Compare what each does, how they make money, and the risks, then decide which fits your thesis and what you already own.
Should you own both LLY and NVO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both before you add the second.
What are the risks of LLY vs NVO?
+
LLY: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LLY or NVO; figures are approximate and dated. Verify current data before investing.